Abstract
Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Cox-2 in cancer cells. Elevated tumor Cox-2 is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. Several experimental and clinical studies have established potent anti-cancer activity of NSAID (Non-steroidal anti-inflammatory drugs) and other Cox-2 inhibitors such as celecoxib. Much attention is being focused on Cox-2 inhibitors as a beneficial target for cancer chemotherapy. The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy.
Keywords: Cyclooxygenase-2 (Cox-2), apoptosis, angiogenesis, cancer, prostaglandin, chemotherapy, radiotherapy, celecoxib, enzyme, arachidonic acid
Current Drug Targets
Title: Biology of Cox-2: An Application in Cancer Therapeutics
Volume: 12 Issue: 7
Author(s): Zakir Khan, Noor Khan, Ram P. Tiwari, Nand K. Sah, GBKS Prasad and Prakash S. Bisen
Affiliation:
Keywords: Cyclooxygenase-2 (Cox-2), apoptosis, angiogenesis, cancer, prostaglandin, chemotherapy, radiotherapy, celecoxib, enzyme, arachidonic acid
Abstract: Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Cox-2 in cancer cells. Elevated tumor Cox-2 is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. Several experimental and clinical studies have established potent anti-cancer activity of NSAID (Non-steroidal anti-inflammatory drugs) and other Cox-2 inhibitors such as celecoxib. Much attention is being focused on Cox-2 inhibitors as a beneficial target for cancer chemotherapy. The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy.
Export Options
About this article
Cite this article as:
Khan Zakir, Khan Noor, P. Tiwari Ram, K. Sah Nand, Prasad GBKS and S. Bisen Prakash, Biology of Cox-2: An Application in Cancer Therapeutics, Current Drug Targets 2011; 12 (7) . https://dx.doi.org/10.2174/138945011795677764
DOI https://dx.doi.org/10.2174/138945011795677764 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Century of Thioxanthones: Through Synthesis and Biological Applications
Current Medicinal Chemistry Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Metallothioneins and Cancer
Current Protein & Peptide Science Discovery of 3,4-Diaminocyclobut-3-ene-1,2-dione-Based CXCR2 Receptor Antagonists for the Treatment of Inflammatory Disorders
Current Topics in Medicinal Chemistry Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Drug Metabolism and Pharmacokinetics in Support of Drug Design
Current Pharmaceutical Design The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design Editorial [Hot Topic: New Developments in the Medicinal Chemistry of Vanilloid TRPV1 and Related Receptors (Guest Editor: Arpad Szallasi)]
Current Topics in Medicinal Chemistry Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Disorders of Sex Development: A Review
Current Women`s Health Reviews TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy
Current Medicinal Chemistry Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology